康方生物-B(09926.HK)新藥獲批內地開展治療晚期惡性腫瘤Ib/II期臨床研究
康方生物-B(09926.HK)公布,公司自主研發的新型腫瘤免疫治療藥物PD-1/VEGF雙特異性抗體(研發代號AK112)獲得中國國家藥品監督管理局藥品審評中心(CDE)批准,開展治療晚期惡性腫瘤的Ib/II期的臨床研究。
集團指,此項臨床研究旨在評估AK112聯合AK117治療晚期惡性腫瘤的安全性、耐受性、藥物代謝動力學、免疫原性、藥效學以及抗腫瘤活性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.